BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Pluristem » Page 4

Pluristem Announces Promising Results from Non-Human Primate Pilot Study of PLX-R18 in Acute Radiation Syndrome

May 8, 2017 By Cade Hildreth (CEO) Leave a Comment

Pluristem PLX-R18 ARS
  • All PLX-treated groups showed improvements in survival rates compared to untreated groups
  • PLX-R18 cells did not increase leukocyte levels in non-irradiated NHPs, indicating no requirement to determine levels of radiation exposure prior to administration
  • Data will inform a pivotal trial that could support marketing authorization under the FDA’s Animal Rule regulatory pathway

[Read more…]

Filed Under: HSCs, Stem Cells Tagged With: acute radiation syndrome, cell therapy, Pluristem, PLX-R18

Governments on Alert and Stockpiling Antidotes for Nuclear Accidents and Attacks

May 2, 2017 By Cade Hildreth (CEO) Leave a Comment

Pluristem PLX-R18 - ARS

Many governments, including the U.S. and Japan, are well aware of the dangers to their populations of exposure to high levels of radiation from nuclear accidents or dirty bomb  attacks. Whereas Japan’s population was recently exposed at Fukushima following the tsunami of 2011, the U.S. Department of Defense has been stockpiling acute radiation syndrome (ARS) countermeasures as a precaution for many years.

The recent escalation of tensions between North Korea and the U.S. may give the American government cause to up its investment in ARS antidotes. During a military parade on April 15th, North Korea displayed weapons including an intercontinental ballistic missile (ICBM) that could be capable of reaching the U.S. ARS may have just become a larger threat to health than it was just a few weeks ago. [Read more…]

Filed Under: HSCs, Stem Cell News, Stem Cells Tagged With: ARS, news, Pluristem, PLX-R18

Pluristem Launches Co-CEO Structure and Appoints New CFO

March 29, 2017 By Cade Hildreth (CEO) Leave a Comment

Pluristem Co-CEO and CFO
  • Yaky Yanay appointed Co-Chief Executive Officer to serve together with Co-Chief Executive Officer Zami Aberman
  • Erez Egozi appointed as Chief Financial Officer

[Read more…]

Filed Under: Stem Cells Tagged With: MSC, placental, Pluristem

Pluristem’s PLX-PAD Cells May Save $1B in Post-Op Costs for Hip Fracture

March 18, 2017 By Cade Hildreth (CEO) Leave a Comment

Pluristem PLX-PAD Cells

The lifetime prevalence of hip fracture in the U.S. is 10% for men and 20% for women. Incidence is expected to continue to rise, driven by an increasing elderly population. Even with today’s surgical repair techniques and post-operative care, at 6 months postinjury, only half of patients can perform their pre-fracture daily living activities.

At 1 year after hip fracture, older adults are five times more likely to be institutionalized than age-matched controls without hip fracture, and mmortality rates resulting from hip fracture range from 12% to 37% within the first year. In parallel, the cost to the U.S. healthcare system is also staggering, and amounts to between $10 and $15 billion annually. [Read more…]

Filed Under: Stem Cell News, Stem Cells Tagged With: cell manufacturing, cell therapy, news, Pluristem, PLX-PAD

Placental-Derived Allogeneic Stem Cells Meet the Needs of the Market and the Patient

March 13, 2017 By Cade Hildreth (CEO) Leave a Comment

Pluristem - PLX Placental Stem Cells

As an increasing number of stem cell therapies advance through clinical trials, the healthcare industry’s focus comes to looking at which cells, allogeneic or autologous, are more likely to be commercially feasible. Proving safety and efficacy for a specific indication is a large enough challenge for any treatment, but for stem cell therapies in particular, commercial viability may be just as big a hurdle.

Pluristem Therapeutics Israel-based Pluristem Therapeutics (NASDAQ:PSTI), may be the only stem cell company that can mass produce immune-privileged allogeneic cells at a scale and price that not only makes them commercially viable, but moreover makes stem cell therapy a preferred method of treatment for patients and payors alike. A proprietary 3D stem cell expansion technology which uses placental-derived cells is the key. [Read more…]

Filed Under: Stem Cells Tagged With: news, placental, Pluristem

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Top Rated Products

  • Job Posting on BioInformant <Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience $297
  • U.S. Cord Blood Banking Survey <Cord Blood Banking Survey of U.S. Parents [2017] $197
  • Exosome Companies 2020 <Global Database of Exosome Companies $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.